Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marketed unapproved drugs workshop

Executive Summary

A public workshop for businesses marketing unapproved drugs will be hosted by FDA Jan. 9. FDA will provide clarification and direction to companies on how to seek drug approval; topics slated for the meeting include NDAs, ANDAs, OTC monographs, application processes, user fees and market exclusivity. The agency is convening the meeting because many companies sought clarification following the June 2006 publication of the agency's Marketed Unapproved Drugs-Compliance Policy Guide (1"The Pink Sheet" June 12, 2006, p. 10)...
Advertisement

Related Content

FDA Crackdown On Unapproved Drugs Has Incentives For Voluntary Submissions
FDA Crackdown On Unapproved Drugs Has Incentives For Voluntary Submissions
Advertisement
UsernamePublicRestriction

Register

PS047753

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel